Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives Average Recommendation of “Hold” from Brokerages

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) have been given a consensus recommendation of “Hold” by the five analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $5.00.

Several research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a research note on Monday. Finally, D. Boral Capital restated a “buy” rating and issued a $6.00 target price on shares of Citius Pharmaceuticals in a report on Wednesday, March 11th.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds have recently modified their holdings of CTXR. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals in the 2nd quarter worth approximately $32,000. NewEdge Advisors LLC purchased a new position in shares of Citius Pharmaceuticals in the second quarter worth $40,000. Asset Advisory Group Inc. purchased a new position in shares of Citius Pharmaceuticals in the fourth quarter worth $46,000. Finally, Heights Capital Management Inc. acquired a new stake in shares of Citius Pharmaceuticals in the fourth quarter worth $622,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Stock Down 26.5%

Shares of NASDAQ CTXR traded down $0.19 on Monday, reaching $0.52. 1,972,197 shares of the company’s stock traded hands, compared to its average volume of 650,802. Citius Pharmaceuticals has a 12 month low of $0.48 and a 12 month high of $2.48. The business’s 50 day simple moving average is $0.79 and its two-hundred day simple moving average is $0.91. The company has a market cap of $11.53 million, a price-to-earnings ratio of -0.21 and a beta of 1.05.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by ($1.34). The company had revenue of $1.67 million for the quarter, compared to the consensus estimate of $18.79 million.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.